Evidence map›Paper›PMID 41954985›Full record

ArticleNucleic acids research2026

Allosteric activation mechanism of the type VII CRISPR-Cas system.

Shuqin Zhang, Yingcan Liu, Wenqi Wu, Zhikun Liu, Qiuqiu He, Tongyao Wang, Jie Yang, Hang Yin, Zhiyong Yuan, Heng Zhang

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuqin ZhangTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Yingcan LiuTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Wenqi WuTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Zhikun LiuTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Qiuqiu HeTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Tongyao WangTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Jie YangTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Hang YinTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
Zhiyong YuanDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
Heng ZhangTianjin Medical University Cancer Institute and Hospital, State Key Laboratory of Experimental Hematology, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, National Clinical Research Center for Cancer, Tianjin Institute of Immunology, Tianjin's Clinical Research Center for Cancer, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.ORCID 0000-0003-1112-7149

Funding

National Natural Science Foundation of China 32571682Natural Science Foundation of Tianjin Municipal Science and Technology Commission 25JCZDJC00740Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-009ATianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-3-004B
6 · The paper itself

Abstract

Type VII CRISPR-Cas system, evolutionarily associated with type III systems, utilizes a Cascade complex formed by Cas5 and catalytically inactive Cas7 copies for target RNA binding, but instead incorporates a specialized Cas14 ribonuclease for target cleavage. Here, we report a high-quality cryo-EM structure at the target engagement state with a shortened crRNA and elucidate how the recruited Cas14 captures the target RNA and undergoes target-mediated activation. The signature Cas14 is homologous to eukaryotic CPSF73 and prokaryotic RNase J, comprising two conserved subdomains, MβL and β-CASP. Different from canonical type III systems, 5'-end target RNA, rather than 3'-end, is bent into the positively charged binding channel formed by the two subdomains to access the conserved catalytic pocket on Cas14. Two special structural features, α1 helix from Cas7 and α10 helix from Cas14, promote the bent target RNA docking into the catalytic pocket of Cas14 nuclease in concert. A dual-functional loop, displaced by the entering target RNA, induces a closed-to-open transition between the two subdomains for nuclease activation. More importantly, the flipped dual-functional loop also maintains the stabilization of incoming target RNA. Altogether, our work provides a more comprehensive understanding of type VII system mechanism, laying a mechanistic foundation for RNA-targeting tool development.

Indexed as

CRISPR-Associated ProteinsCRISPR-Cas SystemsAllosteric RegulationCatalytic DomainCryoelectron MicroscopyModels, MolecularRNACRISPR-Associated ProteinsRNA

Identifiers

PMID41954985
PMCPMC13069675

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.